Evidence map›Paper›PMID 35758198›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2022

Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Ute F Röhrig, Somi Reddy Majjigapu, Pierre Vogel, Aline Reynaud, Florence Pojer, Nahzli Dilek, Patrick Reichenbach, Kelly Ascenção, Melita Irving, George Coukos and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Ute F RöhrigSIB Swiss Institute of Bioinformatics, Molecular Modeling Group, Lausanne, Switzerland.ORCID 0000-0002-4676-4087
Somi Reddy MajjigapuSIB Swiss Institute of Bioinformatics, Molecular Modeling Group, Lausanne, Switzerland.ORCID 0000-0001-6422-5223
Pierre VogelLaboratory of Glycochemistry and Asymmetric Synthesis, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID 0000-0002-7399-2341
Aline ReynaudProtein Production and Structure Core Facility, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID 0000-0002-9694-7383
Florence PojerProtein Production and Structure Core Facility, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID 0000-0002-9183-7206
Nahzli DilekSIB Swiss Institute of Bioinformatics, Molecular Modeling Group, Lausanne, Switzerland.ORCID 0000-0002-3375-2773
Patrick ReichenbachDepartment of Oncology UNIL-CHUV, Ludwig Lausanne Branch, Epalinges, Switzerland.
Kelly AscençãoSIB Swiss Institute of Bioinformatics, Molecular Modeling Group, Lausanne, Switzerland.ORCID 0000-0001-6693-6897
Melita IrvingDepartment of Oncology UNIL-CHUV, Ludwig Lausanne Branch, Epalinges, Switzerland.ORCID 0000-0002-6849-7194
George CoukosDepartment of Oncology UNIL-CHUV, Ludwig Lausanne Branch, Epalinges, Switzerland.ORCID 0000-0001-8813-7367
Olivier MichielinSIB Swiss Institute of Bioinformatics, Molecular Modeling Group, Lausanne, Switzerland.ORCID 0000-0003-4926-6355
Vincent ZoeteSIB Swiss Institute of Bioinformatics, Molecular Modeling Group, Lausanne, Switzerland.ORCID 0000-0002-2336-6537
SIB Swiss Institute of Bioinformatics · CHÉcole Polytechnique Fédérale de Lausanne · CHLudwig Cancer Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The haem enzyme indoleamine 2,3-dioxygenase 1 (IDO1) catalyses the rate-limiting step in the kynurenine pathway of tryptophan metabolism and plays an essential role in immunity, neuronal function, and ageing. Expression of IDO1 in cancer cells results in the suppression of an immune response, and therefore IDO1 inhibitors have been developed for use in anti-cancer immunotherapy. Here, we report an extension of our previously described highly efficient haem-binding 1,2,3-triazole and 1,2,4-triazole inhibitor series, the best compound having both enzymatic and cellular IC

Indexed as

Indoleamine-Pyrrole 2,3,-DioxygenaseTriazolesEnzyme InhibitorsHemeEnzyme InhibitorsHemeIndoleamine-Pyrrole 2,3,-DioxygenaseTriazolesCancer immunotherapystructure-based drug designtryptophan metabolismX-ray crystallography

Identifiers

PMID35758198
PMCPMC9246256
OpenAlexW4283653499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.